Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Focus Partners Advisor Solutions opened a $1.35 million position in Regeneron during the second quarter, purchasing 2,165 shares. Institutional investors collectively own 83.31% of the company.
• Regeneron reported strong quarterly results, with EPS of $14.29 versus the $10.16 consensus estimate and revenue of $4.29 billion, up 16.7% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $793.74.
• The company declared a quarterly dividend of $0.94 per share, while expanding oncology collaborations with Biohaven and Parabilis. However, investors face legal and pipeline risks related to the failed fianlimab-Libtayo melanoma trial and related securities litigation.

Focus Partners Advisor Solutions LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,165 shares of the biopharmaceutical company's stock, valued at approximately $1,350,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Insigneo Advisory Services LLC lifted its position in Regeneron Pharmaceuticals by 3.0% during the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company's stock valued at $343,000 after purchasing an additional 13 shares during the last quarter. Arjuna Capital increased its holdings in shares of Regeneron Pharmaceuticals by 3.2% in the 1st quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company's stock worth $353,000 after buying an additional 14 shares during the last quarter. Guardian Wealth Advisors LLC NC increased its holdings in shares of Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company's stock worth $342,000 after buying an additional 14 shares during the last quarter. TD Private Client Wealth LLC raised its position in shares of Regeneron Pharmaceuticals by 9.7% during the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company's stock valued at $130,000 after buying an additional 15 shares in the last quarter. Finally, MCF Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 15 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $803.48 on Monday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $821.11. The firm has a market cap of $82.73 billion, a price-to-earnings ratio of 19.86, a PEG ratio of 1.37 and a beta of 0.21. The firm has a 50 day moving average price of $675.79 and a 200-day moving average price of $713.99. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm's quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the firm earned $12.81 EPS. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is presently 9.29%.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron is expanding its oncology relationship with Biohaven through a clinical supply agreement to test Biohaven’s BHV-1530 alongside Regeneron’s Libtayo in patients with solid tumors. The combination could strengthen Regeneron’s oncology pipeline if clinical results are favorable. Biohaven-Regeneron Oncology Deal
• Positive Sentiment: Regeneron also entered a strategic research collaboration with Parabilis Medicines to develop antibody-Helicon conjugates. The agreement includes $125 million in upfront consideration and equity investment for Parabilis, with potential milestone payments of up to $2.2 billion plus royalties—highlighting Regeneron’s efforts to broaden its technology base and future pipeline. Parabilis Medicines-Regeneron Collaboration
• Neutral Sentiment: Coverage highlights Regeneron’s exposure to GLP-1-related growth opportunities beyond the leading weight-loss drug makers, although the article provides limited new company-specific financial information. GLP-1 Demand and Regeneron
• Neutral Sentiment: Director Kathryn Guarini sold $320,000 of REGN stock under a pre-arranged Rule 10b5-1 trading plan. Because the sale was scheduled in advance, it is a limited indicator of management’s current outlook.
• Negative Sentiment: Multiple law firms are promoting a securities class action against Regeneron concerning alleged disclosures about the Phase 3 fianlimab-Libtayo melanoma trial. The trial’s failure reportedly erased approximately $11 billion in market value, and the continuing legal notices may keep investor attention focused on potential litigation costs, disclosure risks and weakness in the oncology program. The lead-plaintiff deadline is September 14, 2026. Regeneron Class Action Lawsuit

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an "equal weight" rating in a research report on Friday, July 31st. Royal Bank Of Canada raised their price target on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a "sector perform" rating in a research report on Friday, July 31st. Canaccord Genuity Group dropped their price target on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a "buy" rating for the company in a research note on Tuesday, May 19th. Sanford C. Bernstein upgraded Regeneron Pharmaceuticals to a "hold" rating in a report on Wednesday, July 29th. Finally, Wells Fargo & Company increased their price objective on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an "equal weight" rating in a research report on Friday, July 31st. Sixteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $793.74.

Insider Activity

In other news, Director Arthur F. Ryan sold 200 shares of the firm's stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company's stock, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 31.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,400 shares of company stock valued at $1,090,030. 6.97% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source